ABSTRACT

The ongoing COVID-19 crisis has highlighted the importance of a robust drug supply chain which can be quickly and flexibly ramped up to produce life-saving drug treatments. 3D printing (3DP) of oral solid dosage forms (OSDF) could be a viable part of the emergency drug production response to support vulnerable patients in rural regions and other isolated locations. In the context of the current pandemic, the suitability of different 3DP technologies will depend on the physicochemical properties, unit dose strength and BCS classification of the repurposed drug compounds currently being trialed for COVID-19. Furthermore, the deployment strategy should focus on simplifying dosage forms and formulations, scaling down the size and complexity of the printing systems and real-time quality assurance via process analytical technologies (PAT).

摘要

持续不断的COVID-19危机凸显了强大的药品供应链的重要性，可以快速灵活地增加药品供应链，以生产可挽救生命的药品。口服固体剂型（OSDF）的3D打印（3DP）可能是紧急药物生产响应的可行部分，以支持农村地区和其他偏远地区的弱势患者。在当前大流行的背景下，不同3DP技术的适用性将取决于目前针对COVID-19进行试验的改用药物化合物的理化性质，单位剂量强度和BCS分类。此外，部署策略应集中在简化剂型和配方，缩小打印系统的尺寸和复杂度以及通过过程分析技术（PAT）进行实时质量保证。